{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T02:10:18Z","timestamp":1785895818748,"version":"3.56.0"},"reference-count":150,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T00:00:00Z","timestamp":1731283200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Steroids"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.steroids.2024.109529","type":"journal-article","created":{"date-parts":[[2024,11,10]],"date-time":"2024-11-10T23:15:13Z","timestamp":1731280513000},"page":"109529","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Recent advances in the development of 17beta-hydroxysteroid dehydrogenase inhibitors"],"prefix":"10.1016","volume":"213","author":[{"given":"Donald","family":"Poirier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.steroids.2024.109529_b0005","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1210\/er.2003-0030","article-title":"Overview of steroidogenic enzymes in the pathway from cholesterol to active steroid hormones","volume":"25","author":"Payne","year":"2004","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.steroids.2024.109529_b0010","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.mce.2008.10.040","article-title":"Integrated view on 17beta-hydroxysteroid dehydrogenases","volume":"301","author":"Moeller","year":"2009","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.steroids.2024.109529_b0015","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0039-128X(96)00174-2","article-title":"The key role of 17\u03b2-hydroxysteroid dehydrogenases in sex steroid biology","volume":"62","author":"Labrie","year":"1997","journal-title":"Steroids"},{"key":"10.1016\/j.steroids.2024.109529_b0020","series-title":"Progress in brain research","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0079-6123(08)81010-2","article-title":"The intracrine sex steroid biosynthesis pathways (Chapter 10)","author":"Luu-The","year":"2010"},{"key":"10.1016\/j.steroids.2024.109529_b0025","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/0960-0760(95)00209-X","article-title":"Characteristics of human types 1, 2 and 3 17\u03b2-hydroxysteroid dehydrogenase activities: Oxidation\/reduction and inhibition","volume":"55","author":"Luu-The","year":"1995","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.steroids.2024.109529_b0030","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/S0021-9258(17)38175-9","article-title":"Synthesis of 4-bromoacetamidoestrone methyl ether and study of the steroid binding site of human placenta estradiol 17beta-dehydrogenase","volume":"253","author":"Bhatnagar","year":"1978","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.steroids.2024.109529_b0035","doi-asserted-by":"crossref","first-page":"7694","DOI":"10.1016\/S0021-9258(19)43885-4","article-title":"Photoaffinity labeling of human placental estradiol dehydrogenase with 3-(arylazido-beta-alanine)estrone","volume":"255","author":"Inano","year":"1980","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.steroids.2024.109529_b0040","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3109\/14756369109080057","article-title":"Mechanism based inhibition of hydroxysteroid dehydrogenases","volume":"5","author":"Penning","year":"1991","journal-title":"J. Enzyme Inhib."},{"key":"10.1016\/j.steroids.2024.109529_b0045","series-title":"Design of Enzyme Inhibitors as Drug 2","first-page":"462","article-title":"Inhibitors of hydroxysteroid dehydrogenases: 17\u03b2-hydroxysteroid dehydrogenase","author":"Penning","year":"1994"},{"key":"10.1016\/j.steroids.2024.109529_b0050","first-page":"41","article-title":"17\u03b2-Hydroxysteroid dehydrogenase: inhibitors and inhibitor design, Endocr.-Rel","volume":"3","author":"Penning","year":"1996","journal-title":"Cancer"},{"key":"10.1016\/j.steroids.2024.109529_b0055","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0960-0760(98)00043-0","article-title":"Overview of a rational approach to design type I 17\u03b2-hydroxysteroid dehydrogenase inhibitors without estrogenic activity: Chemical synthesis and biological evaluation","volume":"66","author":"Tremblay","year":"1998","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.steroids.2024.109529_b0060","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0303-7207(00)00427-5","article-title":"Inhibitors of type II 17\u03b2-hydroxysteroid dehydrogenase","volume":"171","author":"Poirier","year":"2001","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.steroids.2024.109529_b0065","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1517\/13543776.11.5.789","article-title":"Inhibitors of steroidogenesis as agents for the treatment of hormone-dependent cancers","volume":"11","author":"Smith","year":"2001","journal-title":"Exp. Opin. Ther. Patents"},{"key":"10.1016\/j.steroids.2024.109529_b0070","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2174\/0929867033368222","article-title":"Inhibitors of 17 beta-hydroxysteroid dehydrogenases","volume":"10","author":"Poirier","year":"2003","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.steroids.2024.109529_b0075","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2174\/187221407780831957","article-title":"Hydroxysteroid dehydrogenase (17\u03b2-HSD3, 17\u03b2-HSD5, and 3\u03b1-HSD3) inhibitors: Extragonadal regulation of intracellular sex steroid hormone levels, Recent Pat","volume":"1","author":"Mohler","year":"2007","journal-title":"Endocr. Metab. Immune Drug Discov."},{"key":"10.1016\/j.steroids.2024.109529_b0080","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1016\/j.ejmech.2008.01.044","article-title":"Design and synthesis of bisubstrate inhibitors of type 1 17\u03b2-hydroxysteroid dehydrogenase: Overview and perspectives","volume":"43","author":"Fournier","year":"2008","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.steroids.2024.109529_b0085","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1677\/ERC-08-0042","article-title":"Design and validation of specific inhibitors of 17beta-hydroxysteroid dehydrogenases for therapeutic application in breast and prostate cancer, and in endometriosis","volume":"15","author":"Day","year":"2008","journal-title":"Endocr.-Relat."},{"key":"10.1016\/j.steroids.2024.109529_b0090","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2174\/092986708783330629","article-title":"Inhibitors of 17\u03b2-hydroxysteroid dehydrogenase type 1","volume":"15","author":"Bro\u017ei\u010d","year":"2008","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.steroids.2024.109529_b0095","doi-asserted-by":"crossref","first-page":"642","DOI":"10.2174\/187152009788680000","article-title":"Advances in development of inhibitors of 17\u03b2-hydroxysteroid dehydrogenases","volume":"9","author":"Poirier","year":"2009","journal-title":"Anti-Cancer Agents Med. Chem."},{"key":"10.1016\/j.steroids.2024.109529_b0100","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1517\/13543776.2010.505604","article-title":"17\u03b2-Hydroxysteroid dehydrogenase inhibitors: a patent review","volume":"20","author":"Poirier","year":"2010","journal-title":"Expert Opin. Ther. Patents"},{"key":"10.1016\/j.steroids.2024.109529_b0105","first-page":"87","article-title":"17\u03b2-Hydroxysteroid dehydrogenase inhibitors","volume":"35","author":"Day","year":"2010","journal-title":"Minerva Endocrinol."},{"key":"10.1016\/j.steroids.2024.109529_b0110","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jsbmb.2010.12.013","article-title":"17\u03b2-Hydroxysteroid dehydrogenases (17\u03b2-HSDs) as therapeutic targets: Protein structures, functions, and recent progress in inhibitor development","volume":"125","author":"Marchais-Oberwinkler","year":"2011","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.steroids.2024.109529_b0115","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jsbmb.2010.12.007","article-title":"Contribution to the development of inhibitors of 17\u03b2-hydroxysteroid dehydrogenase types 1 and 7: Key tools for studying and treating estrogen-dependent diseases","volume":"125","author":"Poirier","year":"2011","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.steroids.2024.109529_b0120","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jsbmb.2010.11.004","article-title":"Inhibitors of type 5 17\u03b2-hydroxysteroid dehydrogenase (AKR1C3): Overview and structural insights","volume":"125","author":"Byrns","year":"2011","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.steroids.2024.109529_b0125","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jsbmb.2013.05.012","article-title":"AKR1C3 as a target in castrate resistant prostate cancer","volume":"137","author":"Adeniji","year":"2013","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.steroids.2024.109529_b0130","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.2174\/15680266113139990004","article-title":"A challenge for medicinal chemistry by the 17\u03b2-hydroxysteroid dehydrogenase superfamily: an integrated biological function and inhibituion study","volume":"13","author":"Lin","year":"2013","journal-title":"Curr. Topics Med. Chem."},{"key":"10.1016\/j.steroids.2024.109529_b0135","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.steroids.2017.02.003","article-title":"Development of 17\u03b2-hydroxysteroid dehydrogenase type 3 as a target in hormone-dependent prostate cancer therapy","volume":"121","author":"Ning","year":"2017","journal-title":"Steroids"},{"key":"10.1016\/j.steroids.2024.109529_b0140","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1080\/13543776.2017.1379503","article-title":"Aldo-keto reductase (AKR) 1C3 inhibitors: a patent review","volume":"27","author":"Penning","year":"2017","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.steroids.2024.109529_b0145","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.mce.2018.10.001","article-title":"Inhibitors of 17\u03b2-hydroxysteroid dehydrogenase type 1, 2, and 14: Structures, biological activities and future challenges","volume":"489","author":"Salah","year":"2019","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.steroids.2024.109529_b0150","doi-asserted-by":"crossref","first-page":"4252","DOI":"10.1021\/acs.jmedchem.8b01530","article-title":"Amyloid-binding alcohol dehydrogenase (ABAD) inhibitors for the treatment of Alzheimer\u2019s disease","volume":"62","author":"Morsy","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.steroids.2024.109529_b0155","doi-asserted-by":"crossref","first-page":"11305","DOI":"10.1021\/acs.jmedchem.9b02138","article-title":"Overview of AKR1C3: Inhibitor achievements and disease insights","volume":"63","author":"Liu","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.steroids.2024.109529_b0160","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/jnc.15027","article-title":"Friend or enemy? Review of 17\u03b2-HSD10 and its role in human health or disease","volume":"155","author":"Vinklarova","year":"2020","journal-title":"J. Neurochem."},{"key":"10.1016\/j.steroids.2024.109529_b0165","doi-asserted-by":"crossref","first-page":"1155558","DOI":"10.3389\/fphar.2023.1155558","article-title":"Targeting the formation of estrogens for treatment of hormone dependent diseases-current status","volume":"14","author":"Ri\u017ener","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.steroids.2024.109529_b0170","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1080\/14756366.2016.1204610","article-title":"Comparative investigation of the in vitro inhibitory potencies of 13-epimeric estrones and D-secoestrones towards 17\u03b2-hydroxysteroid dehydrogenase type 1","volume":"31","author":"Herman","year":"2016","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.steroids.2024.109529_b0175","doi-asserted-by":"crossref","first-page":"574","DOI":"10.3109\/14756366.2015.1050008","article-title":"Synthesis and in vitro pharmacological evaluation of N-[(1-benzyl-1,2,3-triazol-4-yl)methyl]-carboxamides on D-secoestrone scaffolds","volume":"31","author":"Szab\u00f3","year":"2016","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.steroids.2024.109529_b0180","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.steroids.2015.10.008","article-title":"Synthesis of A-ring halogenated 13\u03b1-estrone derivatives as potential 17\u03b2-HSD1 inhibitors","volume":"104","author":"Bacsa","year":"2015","journal-title":"Steroids"},{"key":"10.1016\/j.steroids.2024.109529_b0185","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1080\/14756366.2018.1490731","article-title":"Synthesis and structure-activity relationships of 2- and\/or 4-halogenated 13\u03b2- and 13\u03b1-estrone derivatives as enzyme inhibitors of estrogen biosynthesis","volume":"33","author":"Bacsa","year":"2018","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.steroids.2024.109529_b0190","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.3762\/bjoc.14.262","article-title":"Pd-Catalyzed microwave-assisted synthesis of phosphonated 13\u03b1-estrones as potential OATP2B1, 17\u03b2-HSD1 and\/or STS inhibitors","volume":"14","author":"J\u00f3j\u00e1rt","year":"2018","journal-title":"Beilstein J. Org. Chem."},{"key":"10.1016\/j.steroids.2024.109529_b0195","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.3762\/bjoc.13.126","article-title":"Synthesis of novel 13\u03b1-estrone derivatives by Sonogashira coupling as potential 17\u03b2-HSD1 inhibitors","volume":"13","author":"Bacsa","year":"2017","journal-title":"Beilstein J. Org. Chem."},{"key":"10.1016\/j.steroids.2024.109529_b0200","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1080\/14756366.2019.1634064","article-title":"Synthesis of substituted 15\u03b2-alkoxy estrone derivatives and their cofactor-dependent inhibitory effect on 17\u03b2-HSD1","volume":"34","author":"Herman","year":"2019","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.steroids.2024.109529_b0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsbmb.2021.105997","article-title":"Heterocyclic androstane and estrane D-ring modified steroids: Microwave-asisted synthesis, steroid-converting enzyme inhibition, apoptosis induction, and effects on genes encoding estrogen inactivating enzymes","volume":"214","author":"Kulm\u00e1ny","year":"2021","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.steroids.2024.109529_b0210","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ejmech.2015.04.024","article-title":"Probing the origins of 17\u03b2-hydroxysteroid dehydrogenase type 1 inhibitory activity via QSAR and molecular cocking","volume":"96","author":"Srungboonmee","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.steroids.2024.109529_b0215","doi-asserted-by":"crossref","first-page":"20319","DOI":"10.1039\/D2RA03092F","article-title":"Anticancer potential of \u03b2-sitosterol and oleanolic acid as through inhibition of human estrogenic 17beta-hydroxysteroid dehydrogenase type-1 based on an in silico approach","volume":"12","author":"Kristanti","year":"2022","journal-title":"RSC Adv."},{"key":"10.1016\/j.steroids.2024.109529_b0220","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1111\/febs.14784","article-title":"Crystal structures of human 17\u03b2-hydroxysteroid dehydrogenase type 1 complexed with estrone and NADP+ reveal the mechanism of substrate inhibition","volume":"286","author":"Li","year":"2019","journal-title":"FEBS J."},{"key":"10.1016\/j.steroids.2024.109529_b0225","doi-asserted-by":"crossref","first-page":"632","DOI":"10.3390\/molecules28020632","article-title":"Chemical synthesis and biological evaluation of 3-substituted estrone\/estradiol derivatives as 17\u03b2-hydroxysteroid dehydrogenase type 1 inhibitors acting via a reverse orientation of the natural substrate estrone","volume":"28","author":"Ngueta","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.steroids.2024.109529_b0230","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jsbmb.2015.10.020","article-title":"Impact of structural modifications at positions 13, 16 and 17 of 16\u03b2-(m-carbamoylbenzyl)-estradiol on 17\u03b2-hydroxysteroid dehydrogenase type 1 inhibition and estrogenic activity","volume":"161","author":"Maltais","year":"2016","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.steroids.2024.109529_b0235","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.steroids.2018.09.009","article-title":"Chemical synthesis of C3-oxiranyl\/oxiranylmethyl-estrane derivatives targeted by molecular modeling and tested as potential inhibitors of 17\u03b2-hydroxysteroid dehydrogenase type 1","volume":"140","author":"Lesp\u00e9rance","year":"2018","journal-title":"Steroids"},{"key":"10.1016\/j.steroids.2024.109529_b0240","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2174\/1573408017666211008141335","article-title":"Targeting histidine for developing a new generation of covalent enzyme inhibitors","volume":"17","author":"Poirier","year":"2012","journal-title":"Curr. Enz. Inhib."},{"key":"10.1016\/j.steroids.2024.109529_b0245","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1021\/acs.oprd.8b00402","article-title":"Development of a gram-scale synthesis of PBRM, an irreversible inhibitor of 17\u03b2-hydroxysteroid dehydrogenase type 1","volume":"23","author":"Maltais","year":"2019","journal-title":"Org. Process Res. Dev."},{"key":"10.1016\/j.steroids.2024.109529_b0250","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jsbmb.2017.12.007","article-title":"Pharmacokinetic profile of PBRM in rodents, a first selective inhibitor of 17\u03b2-HSD1 for breast cancer and endometriosis treatments","volume":"178","author":"Maltais","year":"2018","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.steroids.2024.109529_b0255","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.bcp.2017.08.004","article-title":"Insight into the mode of action and selectivity of PBRM, a covalent steroidal inhibitor of 17\u03b2-hydroxysteroid dehydrogenase type 1","volume":"144","author":"Trottier","year":"2017","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.steroids.2024.109529_b0260","doi-asserted-by":"crossref","first-page":"5275","DOI":"10.1021\/acs.jpclett.8b02225","article-title":"Combined biophysical chemistry reveals a new covalent inhibitor with low-reactivity alkyl halide","volume":"9","author":"Li","year":"2018","journal-title":"J. Phys. Chem. Lett."},{"key":"10.1016\/j.steroids.2024.109529_b0265","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.3390\/cancers13081841","article-title":"A targeted-covalent inhibitor of 17\u03b2-HSD1 blocks two estrogen-biosynthesis pathways: In vitro (metabolism) and in vivo (xenograft) studies in T-47D breast cancer models","volume":"13","author":"Poirier","year":"2012","journal-title":"Cancers"},{"key":"10.1016\/j.steroids.2024.109529_b0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsbmb.2022.106136","article-title":"An irreversible inhibitor of 17\u03b2-hydroxysteroid dehydrogenase type 1 inhibits estradiol synthesis in human endometriosis lesions and induces regression of the non-human primate endometriosis","volume":"222","author":"Poirier","year":"2022","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.steroids.2024.109529_b0275","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1021\/acsmedchemlett.1c00462","article-title":"17\u03b2-Hydroxysteroid dehydrogenase type 1 inhibition: A potential treatment option for non-small cell lung cancer","volume":"12","author":"Gargano","year":"2011","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.steroids.2024.109529_b0280","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.3390\/ijms18092007","article-title":"Interference of paraben compounds with estrogen metabolism by inhibition of 17\u03b2-hydroxysteroid dehydrogenases","volume":"18","author":"Engeli","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.steroids.2024.109529_b0285","doi-asserted-by":"crossref","first-page":"14061","DOI":"10.1021\/acsomega.0c01519","article-title":"Synthesis of 1,4-biphenyl-triazole derivatives as possible 17\u03b2-HSD1 inhibitors: An in silico study","volume":"5","author":"Hern\u00e1ndez-L\u00f3pez","year":"2020","journal-title":"ACS Omega"},{"key":"10.1016\/j.steroids.2024.109529_b0290","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/cmdc.202000762","article-title":"N-phenyl-1,2,3,4-tetrahydroisoquinoline: An alternative scaffold for the design of 17\u03b2-hydroxysteroid dehydrogenase 1 inhibitors","volume":"16","author":"Mortinelli","year":"2021","journal-title":"ChemMedChem"},{"key":"10.1016\/j.steroids.2024.109529_b0295","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1021\/jm1009082","article-title":"New drug-like hydroxyphenylnaphthol steroidomimetics as potent and selective 17\u03b2-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of estrogen-dependent diseases","volume":"54","author":"Marchais-Oberwinkler","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.steroids.2024.109529_b0300","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.3390\/molecules27123962","article-title":"Halogen-based 17\u03b2-HSD1 inhibitors: Insights from DFT, docking, and molecular dynamics simulation studies","volume":"27","author":"Kulandaisamy","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.steroids.2024.109529_b0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.fct.2023.114052","article-title":"Bisphenol analogues inhibit human and rat 17\u03b2-hydroxysteroid dehydrogenase 1: 3D-quantitative structure-activity relationship (3D-QSAR) and in silico docking analysis","volume":"181","author":"Chen","year":"2023","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.steroids.2024.109529_b0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsbmb.2024.106510","article-title":"Effect of organochlorine pesticides on human and rat 17\u03b2-hydroxysteroid dehydrogenase 1 activity: Structure-activity relationship and in silico docking analysis","volume":"240","author":"Gong","year":"2024","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.steroids.2024.109529_b0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.ecoenv.2024.116173","article-title":"Per- and polyfluoroalkyl substances inhibit human and rat 17\u03b2-hydroxysteroid dehydrogenase 1: Quantitative structure-activity relationship and molecular docking analysis","volume":"273","author":"Wen","year":"2024","journal-title":"Ecotoxicol. Environ. Saf."},{"key":"10.1016\/j.steroids.2024.109529_b0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.steroids.2021.108856","article-title":"Synthesis of 16\u03b2-derivatives of 3-(2-bromoethyl)-estra-1,3,5(10)-trien-17\u03b2-ol as inhibitors of 17\u03b2-HSD1 and\/or steroid sulfatase for the treatment of estrogen-dependent diseases","volume":"172","author":"Lesp\u00e9rance","year":"2021","journal-title":"Steroids"},{"key":"10.1016\/j.steroids.2024.109529_b0325","doi-asserted-by":"crossref","first-page":"11726","DOI":"10.1021\/acs.jmedchem.2c00589","article-title":"Dual targeting of steroid sulfatase and 17\u03b2-hydroxysteroid dehydrogenase type 1 by a novel drug-prodrug approach: A potential therapeutic option for the treatment of endometriosis","volume":"65","author":"Mohamed","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.steroids.2024.109529_b0330","doi-asserted-by":"crossref","first-page":"8975","DOI":"10.1021\/acs.jmedchem.3c00571","article-title":"Potent dual inhibitors of steroid sulfatase and 17\u03b2-hydroxysteroid dehydrogenase type 1 with a suitable pharmacokinetic profile for in vivo proof-of-principle studies in an endometriosis mouse model","volume":"66","author":"Salah","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.steroids.2024.109529_b0335","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1021\/acs.jmedchem.8b01493","article-title":"Targeted endocrine therapy: Design, synthesis, and proof-of-principle of 17\u03b2-hydroxysteroid dehydrogenase type 2 inhibitors in bone fracture healing","volume":"62","author":"Abdelsamie","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.steroids.2024.109529_b0340","doi-asserted-by":"crossref","first-page":"10724","DOI":"10.1021\/acs.jmedchem.8b01373","article-title":"Highly potent 17\u03b2-HSD2 inhibitors with a promising pharmacokinetic profile for targeted osteoporosis therapy","volume":"61","author":"Siebenb\u00fcrger","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.steroids.2024.109529_b0345","doi-asserted-by":"crossref","first-page":"7289","DOI":"10.1021\/acs.jmedchem.9b00932","article-title":"Design, synthesis, and biological characterization of orally active 17\u03b2-hydroxysteroid dehydrogenase type 2 inhibitors targeting the prevention of osteoporosis","volume":"62","author":"Abdelsamie","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.steroids.2024.109529_b0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsbmb.2019.105405","article-title":"Effects of 17\u03b2-HSD2 inhibition in bones on osteoporosis based on an animal rat model","volume":"192","author":"M\u00fcller","year":"2019","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.steroids.2024.109529_b0355","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ejmech.2019.05.084","article-title":"Development of potential preclinical candidates with promising in vitro ADME profile for the inhibition of type 1 and type 2 17\u03b2-hydroxysteroid dehydrogenases: Design, synthesis, and biological evaluation","volume":"178","author":"Abdelsamie","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.steroids.2024.109529_b0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsbmb.2020.105790","article-title":"Homology modeling meets site-directed mutagenesis: An ideal combination to elucidate the topology of 17\u03b2-HSD2","volume":"206","author":"Sager","year":"2021","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.steroids.2024.109529_b0365","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ejmech.2015.08.030","article-title":"Towards the evaluation in an animal disease model: Fluorinated 17\u03b2-HSD1 inhibitors showing strong activity towards both the human and the rat enzyme","volume":"103","author":"Abdelsamie","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.steroids.2024.109529_b0370","doi-asserted-by":"crossref","first-page":"657","DOI":"10.2119\/molmed.2010.00143","article-title":"Steroidogenic enzymes and stem cell markers are upregulated during androgen deprivation in prostate cancer","volume":"17","author":"Pfeiffer","year":"2011","journal-title":"Mol. Med."},{"key":"10.1016\/j.steroids.2024.109529_b0375","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/j.bmcl.2016.03.069","article-title":"Synthesis of a dansyl-labeled inhibitor of 17\u03b2-hydroxysteroid dehydrogenase type 3 for optical imaging","volume":"26","author":"Kenmogne","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.steroids.2024.109529_b0380","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2174\/1573408016999200729110245","article-title":"Insight into the mechanism of 17\u03b2-hydroxysteroid dehydrogenase type 3 inhibition by the androsterone derivatives RM-532-105","volume":"16","author":"Stephen","year":"2020","journal-title":"Curr. Enz. Inhib."},{"key":"10.1016\/j.steroids.2024.109529_b0385","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0171871","article-title":"Investigation of the in vitro and in vivo efficiency of RM-532-105, a 17\u03b2-hydroxysteroid dehydrogenase type 3 inhibitor, in LAPC-4 prostate cancer cell and tumor models","volume":"12","author":"Kenmogne","year":"2017","journal-title":"PLoS ONE"},{"key":"10.1016\/j.steroids.2024.109529_b0390","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.106145","article-title":"Chemical synthesis of fluorinated and iodinated 17\u03b2-HSD3 inhibitors and evaluation for imaging prostate cancer tumors and tissue biodistribution","volume":"129","author":"Poirier","year":"2022","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.steroids.2024.109529_b0395","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/j.bmc.2017.02.008","article-title":"Impact of androstane A- and D- ring inversion on 17\u03b2-hydroxysteroid dehydrogenase type 3 inhibitory activity, androgenic effect and metabolic stability","volume":"25","author":"Cort\u00e9s-Ben\u00edtez","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.steroids.2024.109529_b0400","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsbmb.2021.105846","article-title":"16-Picolyl-androsterone derivative exhibits potent 17\u03b2-HSD3 inhibitory activity, improved metabolic stability and cytotoxic effect on various cancer cells: Synthesis, homology modeling and docking studies","volume":"210","author":"Cort\u00e9s-Ben\u00edtez","year":"2021","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.steroids.2024.109529_b0405","doi-asserted-by":"crossref","first-page":"7070","DOI":"10.1021\/acs.jmedchem.9b00624","article-title":"A- and D- ring structural modifications of an androsterone derivative inhibiting 17\u03b2-hydroxysteroid dehydrogenase type 3: Chemical synthesis and structure-activity relationships","volume":"62","author":"Cort\u00e9s-Ben\u00edtez","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.steroids.2024.109529_b0410","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1530\/ERC-12-0231","article-title":"STX2171, a 17\u03b2-hydroxysteroid dehydrogenase type 3 inhibitor, is efficacious in vivo in a novel hormone-dependent prostate cancer model","volume":"20","author":"Day","year":"2013","journal-title":"Endocr.-Relat."},{"key":"10.1016\/j.steroids.2024.109529_b0415","doi-asserted-by":"crossref","first-page":"7166","DOI":"10.3390\/molecules26237166","article-title":"Substituted aryl benzylamines as potent and selective inhibitors of 17\u03b2-hydroxysteroid dehydrogenase type 3","volume":"26","author":"Vicker","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.steroids.2024.109529_b0420","first-page":"1113","article-title":"Rapid and efficient microwave-assisted Friedl\u00e4nder quinoline synthesis","volume":"9","author":"Bailey","year":"2020","journal-title":"Chemistry Open"},{"key":"10.1016\/j.steroids.2024.109529_b0425","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.bmcl.2009.10.111","article-title":"Coumarins as novel 17\u03b2-hydroxysteroid dehydrogenase type 3 inhibitors for potential treatment of prostate cancer","volume":"20","author":"Harada","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.steroids.2024.109529_b0430","first-page":"966","article-title":"QSAR study of 17\u03b2-HSD3 inhibitors by genetic algorithm-support vector machine as a target receptor for the treatment of prostate cancer, Iran","volume":"16","author":"Pourbasheer","year":"2017","journal-title":"J. Pharm. Res."},{"key":"10.1016\/j.steroids.2024.109529_b0435","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ejmech.2014.03.012","article-title":"Synthesis of novel curcumin analogues for inhibition of 11\u03b2-hydroxysteroid dehydrogenase type 1 with anti-diabetic properties","volume":"77","author":"Yuan","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.steroids.2024.109529_b0440","doi-asserted-by":"crossref","first-page":"637","DOI":"10.3389\/fphar.2020.00637","article-title":"The curcumin derivative, H10, suppresses hormone-dependent prostate cancer by inhibiting 17\u03b2-hydroxysteroid dehydrogenase type 3","volume":"11","author":"Cheng","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.steroids.2024.109529_b0445","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1248\/cpb.c20-00242","article-title":"Preclinical pharmacokinetics, tissue distribution and primary safety evaluation of a novel curcumin analogue H10 suspension, a potential 17\u03b2-hydroxysteroid dehydrogenase type 3 inhibitor","volume":"69","author":"Xiao","year":"2021","journal-title":"Chem. Pharm. Bull."},{"key":"10.1016\/j.steroids.2024.109529_b0450","doi-asserted-by":"crossref","DOI":"10.1016\/j.fct.2024.114489","article-title":"Demethoxylation of curcumin enhances its inhibition on human and rat 17\u03b2-hydroxysteroid dehydrogenase 3: QSAR structure-activity relationship and in silico docking analysis","volume":"186","author":"Ji","year":"2024","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.steroids.2024.109529_b0455","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2022.109822","article-title":"Reduction of photoswitched, nitrogen bridged N-acetyl diazocines limits inhibition of 17\u03b2HSD3 activity in transfected human embryonic kidney 293 cells","volume":"354","author":"Wages","year":"2022","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.steroids.2024.109529_b0460","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2024.110872","article-title":"Light-switchable diazocines as potential inhibitors of testosterone-synthesizing 17\u03b2-hydroxysteroid dehydrogenase 3","volume":"390","author":"Wages","year":"2024","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.steroids.2024.109529_b0465","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jsbmb.2018.06.013","article-title":"11-Oxygenated androgen precursors are the preferred substrates for aldo-keto reductase 1C3 (AKR1C3): implications for castration resistant prostate cancer","volume":"183","author":"Barnard","year":"2018","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.steroids.2024.109529_b0470","doi-asserted-by":"crossref","first-page":"bqac068","DOI":"10.1210\/endocr\/bqac068","article-title":"Conversion of classical and 11-oxygenated androgens by insulin-induced AKR1C3 in a model of human PCOS adipocytes","author":"Paulukinas","year":"2022","journal-title":"Endocrinology 163"},{"key":"10.1016\/j.steroids.2024.109529_b0475","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.mce.2018.07.002","article-title":"AKR1C3 (type 5 17\u03b2-hydroxysteroid dehydrogenase\/prostaglandin F synthase): Roles in malignancy and endocrine disorders","volume":"489","author":"Penning","year":"2019","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.steroids.2024.109529_b0480","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104446","article-title":"Aldo-keto reductase 1C3\u2013Assessment as a new target for the treatment of endometriosis","volume":"152","author":"Ri\u017ener","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.steroids.2024.109529_b0485","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s40268-023-00427-5","article-title":"Hepatotoxicity of AKR1C3 inhibitor BAY1128688: Findings from an early terminated phase IIa trial for the treatment of endometriosis","volume":"23","author":"Hilpert","year":"2023","journal-title":"Drugs in R&d"},{"key":"10.1016\/j.steroids.2024.109529_b0490","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/ejendo\/lvad063","article-title":"Novel aldo-keto reductase 1C3 inhibitor affects androgen metabolism but not ovarian function in healthy women: a phase study","volume":"189","author":"Gashaw","year":"2023","journal-title":"Eur. J. Endocrinol"},{"key":"10.1016\/j.steroids.2024.109529_b0495","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.cbi.2014.12.015","article-title":"Screening baccharin analogs as selective inhibitors against type 5 17\u03b2-hydroxysteroid dehydrogenase (AKR1C3)","volume":"234","author":"Zang","year":"2015","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.steroids.2024.109529_b0500","doi-asserted-by":"crossref","first-page":"5220","DOI":"10.1016\/j.bmc.2014.08.007","article-title":"Synthesis of non-prenyl analogues of baccharin as selective and potent inhibitors for aldo-keto reductase 1C3","volume":"22","author":"Endo","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.steroids.2024.109529_b0505","first-page":"1833","article-title":"AKR1C3 inhibitor KV-37 exibits antineoplastic effects and potentiates enzalutamide in combination therapy in prostate adenocarcinoma cells","volume":"17","author":"Verma","year":"2018","journal-title":"Mol. Cell. Ther."},{"key":"10.1016\/j.steroids.2024.109529_b0510","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1021\/acsmedchemlett.6b00163","article-title":"Selective AKR1C3 inhibitors potentiate chemotherapeutic activity in multiple acute myeloid leukemia (AML) cell lines","volume":"7","author":"Verma","year":"2016","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.steroids.2024.109529_b0515","doi-asserted-by":"crossref","first-page":"3590","DOI":"10.1021\/acs.jmedchem.9b00090","article-title":"Potent and highly selective aldo-keto reductase 1C3 (AKR1C3) inhibitors act as chemotherapeutic potentiators in acute myeloid leukemia and T-cell acute lymphoblastic leukemia","volume":"62","author":"Verma","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.steroids.2024.109529_b0520","doi-asserted-by":"crossref","first-page":"9894","DOI":"10.1021\/acs.jmedchem.3c00732","article-title":"Aldo-keto reductase 1C3 inhibitor prodrug improves pharmacokinetic profile and demonstrates in vivo efficacy in a prostate cancer xenograft model","volume":"66","author":"Maddeboina","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.steroids.2024.109529_b0525","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s42004-024-01177-4","article-title":"Discovery of an aldo-keto reductase 1C3 (AKR1C3) degrader","volume":"7","author":"Carmona","year":"2024","journal-title":"Commun. Chem."},{"key":"10.1016\/j.steroids.2024.109529_b0530","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.ejmech.2017.08.046","article-title":"Hydroxytriazole derivatives as potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors discovered by bioisosteric scaffold hopping approach","volume":"139","author":"Pippione","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.steroids.2024.109529_b0535","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.ejmech.2018.03.040","article-title":"Potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors based on the benzoisoxazole moiety: application of a bioisosteric scaffold hopping approach to flufenamic acid","volume":"150","author":"Pippione","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.steroids.2024.109529_b0540","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116193","article-title":"Structure-guided optimization of 3-hydroxybenzoisoxazole derivatives as inhibitors of aldo-keto reductase 1C3 (AKR1C3) to target prostate cancer","volume":"268","author":"Pippione","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.steroids.2024.109529_b0545","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1021\/jm3017656","article-title":"Development of potent and selective indomethacin analogues for the inhibition of AKR1C3 (type 5 17\u03b2-hydroxysteroid dehydrogenase\/prostaglandin F synthase) in castrate-resistant prostate cancer","volume":"56","author":"Liedtke","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.steroids.2024.109529_b0550","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1021\/jm201547v","article-title":"Development of potent and selective inhibitors of aldo-keto reductase 1C3 (type 5 17\u03b2-hydroxysteroid dehydrogenase) based on N-phenyl-aminobenzoates and their structure activity relationships","volume":"55","author":"Adeniji","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.steroids.2024.109529_b0555","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1021\/acsmedchemlett.8b00484","article-title":"Bioisosteres of indomethacin as inhibitors of aldo-keto reductase 1C3","volume":"10","author":"Lolli","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.steroids.2024.109529_b0560","doi-asserted-by":"crossref","first-page":"10396","DOI":"10.1021\/acs.jmedchem.0c00939","article-title":"Development of novel AKR1C3 inhibitors as new potential treatment for castration-resistant prostate cancer","volume":"63","author":"Endo","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.steroids.2024.109529_b0565","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1021\/acsmedchemlett.2c00175","article-title":"Discovery of novel aldo-keto reductase 1C3 inhibitors as chemotherapeutic potentiators for cancer drug resistance","volume":"13","author":"He","year":"2022","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.steroids.2024.109529_b0570","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.115013","article-title":"Development of highly potent and specific AKR1C3 inhibitors chemosensitivity of drug-resistant breast cancer","volume":"247","author":"Liu","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.steroids.2024.109529_b0575","doi-asserted-by":"crossref","first-page":"9537","DOI":"10.1021\/acs.jmedchem.3c00213","article-title":"Development of biaryl-containing aldo-keto reductase 1C3 (AKR1C3) inhibitors for reversing AKR1C3-mediated drug resistance in cancer treatment","volume":"66","author":"He","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.steroids.2024.109529_b0580","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.3390\/cancers12082092","volume":"12","author":"Kafka","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.steroids.2024.109529_b0585","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3390\/metabo12020099","article-title":"Analogues of natural chalcones as efficient inhibitors of AKR1C3","volume":"12","author":"M\u00f6ller","year":"2022","journal-title":"Metabolites"},{"key":"10.1016\/j.steroids.2024.109529_b0590","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s40011-021-01335-x","article-title":"Identification of novel inhibitor for aldo-keto reductase 1 C3 by virtual screening of PubChem database","volume":"92","author":"Pourabouk","year":"2022","journal-title":"Proc. Natl. Acad. Sci. India Sect. B Biol. Sci."},{"key":"10.1016\/j.steroids.2024.109529_b0595","doi-asserted-by":"crossref","first-page":"12668","DOI":"10.1080\/07391102.2023.2175265","article-title":"Molecular docking, 3D-QSAR and simulation studies for identifying pharmacophoric features of indole derivatives as 17\u03b2-hydroxysteroid dehydrogenase type 5 (17\u03b2-HSD5) inhibitors","volume":"41","author":"Kulkarni","year":"2023","journal-title":"J. Biomol. Struc. Dyn."},{"key":"10.1016\/j.steroids.2024.109529_b0600","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.3390\/molecules29081802","article-title":"Design and evaluation of NSAID derivatives as AKR1C3 inhibitors for breast cancer treatment through computer-aided drug design and in vitro analysis","volume":"29","author":"Fonseca-Ben\u00edtez","year":"2024","journal-title":"Molecules"},{"key":"10.1016\/j.steroids.2024.109529_b0605","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-24-0440","article-title":"LX1 targets androgen receptor variants and AKR1C3 to overcome therapy resistance in advanced prostate cancer","author":"Ning","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.steroids.2024.109529_b0610","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsbmb.2021.105963","article-title":"The multi-specific human 17 beta-hydroxysteroid dehydrogenase type 7: Non-competitive inhibitors can target different catalyses to facilitate breast cancer treatment","volume":"214","author":"Th\u00e9riault","year":"2021","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.steroids.2024.109529_b0615","doi-asserted-by":"crossref","first-page":"7488","DOI":"10.1021\/jm900921c","article-title":"Potent and selective steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 7, an enzyme that catalyzes the reduction of key hormones estrone and dihydrotestosterone","volume":"52","author":"Bellavance","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.steroids.2024.109529_b0620","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.biochi.2019.12.012","article-title":"Multiple catalytic activities of human 17\u03b2-hydroxysteroid dehydrogenase type 7 respond differently to inhibitors","volume":"170","author":"Ferrante","year":"2020","journal-title":"Biochimie"},{"key":"10.1016\/j.steroids.2024.109529_b0625","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsbmb.2024.106544","article-title":"Synthesis and characterization of targeted 17\u03b2-hydroxysteroid dehydrogenase type 7 inhibitors","volume":"242","author":"Sanc\u00e9au","year":"2024","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.steroids.2024.109529_b0630","unstructured":"S.X. Lin, D. Poirier, J.Y. Sanc\u00e9au, R. Maltais, Novel inhibitors of 17\u03b2-HSD7 and uses thereof, Universit\u00e9 Laval, WO2022261774A1, 2022."},{"key":"10.1016\/j.steroids.2024.109529_b0635","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mce.2011.06.011","article-title":"Hydroxysteroid (17\u03b2) dehydrogenase X in human health and disease","volume":"343","author":"Yang","year":"2011","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.steroids.2024.109529_b0640","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jsbmb.2014.07.001","article-title":"Roles of 17\u03b2-hydroxysteroid dehydrogenase type 10 in neurodegenerative disorders","volume":"143","author":"Yang","year":"2014","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.steroids.2024.109529_b0645","doi-asserted-by":"crossref","first-page":"47","DOI":"10.5483\/BMBRep.2020.53.1.279","article-title":"Mitochondrial dysfunction and Alzheimer\u2019s disease: prospects for therapeutic intervention","volume":"53","author":"Lim","year":"2020","journal-title":"BMB Rep."},{"key":"10.1016\/j.steroids.2024.109529_b0650","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.2174\/0929867322666150114163051","article-title":"A direct interaction between mitochondrial proteins and amyloid-\u03b2 peptide and its significance for the progression and treatment of Alzheimer\u2019s disease","volume":"22","author":"Benek","year":"2015","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.steroids.2024.109529_b0655","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.tem.2005.03.006","article-title":"Multiple functions of type 10 17\u03b2-hydroxysteroid dehydrogenase","volume":"16","author":"Yang","year":"2005","journal-title":"TRENDS Endocrin. Met."},{"key":"10.1016\/j.steroids.2024.109529_b0660","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1016\/j.bmcl.2018.09.031","article-title":"Identification of steroidal derivatives inhibiting the transformations of allopregnanolone and estradiol by 17\u03b2-hydroxysteroid dehydrogenanse type 10","volume":"28","author":"Boutin","year":"2018","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.steroids.2024.109529_b0665","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112909","article-title":"Synthesis of 17\u03b2-hydroxysteroid dehydrogenase type 10 steroidal inhibitors: Selectivity, metabolic stability and enhanced potency","volume":"209","author":"Boutin","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.steroids.2024.109529_b0670","doi-asserted-by":"crossref","first-page":"12116","DOI":"10.1021\/acsomega.3c10148","article-title":"C-3 steroidal hemiesters as inhibitors of 17\u03b2-hydroxysteroid dehydrogenase type 10","volume":"9","author":"Hanzlova","year":"2024","journal-title":"ACS Omega"},{"key":"10.1016\/j.steroids.2024.109529_b0675","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115593","article-title":"Development of submicromolar 17\u03b2-HSD10 inhibitors and their in vitro and in vivo evaluation","volume":"258","author":"Benek","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.steroids.2024.109529_b0680","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/jnc.15917","article-title":"Physiologically relevant fluorescent assay for the identification of 17\u03b2-HSD10 inhibitors","volume":"167","author":"Schmidt","year":"2023","journal-title":"J. Neurochem."},{"key":"10.1016\/j.steroids.2024.109529_b0685","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1021\/acsmedchemlett.3c00355","article-title":"Nanomolar benzothiazole-based inhibitors of 17\u03b2-HSD10 with cellular bioactivity","volume":"14","author":"Hanzlova","year":"2023","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.steroids.2024.109529_b0690","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.toxlet.2020.12.012","article-title":"Effects of novel 17\u03b2-hydroxysteroid dehydrogenase type 10 inhibitors on mitochondrial respiration","volume":"339","author":"Fi\u0161ar","year":"2012","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.steroids.2024.109529_b0695","doi-asserted-by":"crossref","first-page":"134","DOI":"10.2174\/157340811798807614","article-title":"Synthesis and evaluation of amido-deoxyestradiol derivatives as inhibitors of 17\u03b2-hydroxysteroid dehydrogenase type 12","volume":"7","author":"Farhane","year":"2011","journal-title":"Curr. Enz. Inhib."},{"key":"10.1016\/j.steroids.2024.109529_b0700","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1038\/s41598-020-61051-w","article-title":"Very-long-chain fatty acid metabolic capacity of 17-beta-hydroxysteroid dehydrogenase type 12 (HSD17B12) promotes replication of hepatitis C virus and related flaviviruses","volume":"10","author":"Mohamed","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.steroids.2024.109529_b0705","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1056\/NEJMoa1712191","article-title":"A protein-truncating HSD17B13 variant and protection from chronic liver disease","volume":"378","author":"Abul-Husn","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.steroids.2024.109529_b0710","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1021\/acs.jmedchem.2c01884","article-title":"Discovery of a novel potent and selective HSD17B13 inhibitor, BI-3231, a well-characterized chemical probe available for open science","volume":"66","author":"Thamm","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.steroids.2024.109529_b0715","unstructured":"Molecules for free. Collaborations for science, Boehringer Ingelheim International. https:\/\/opnMe.com, 2022 (accessed December 18, 2022)."},{"key":"10.1016\/j.steroids.2024.109529_b0720","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/d41573-022-00071-9","article-title":"Vlach et al, opnMe.com: a digital initiative for sharing tools with the biomedical research community","volume":"21","author":"Gollner","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.steroids.2024.109529_b0725","doi-asserted-by":"crossref","first-page":"5158","DOI":"10.1038\/s41467-023-40766-0","article-title":"Structural basis of lipid-droplet localization of 17\u03b2-hydroxysteroid dehydrogenase 13","volume":"14","author":"Liu","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.steroids.2024.109529_b0730","doi-asserted-by":"crossref","first-page":"6961","DOI":"10.1021\/acs.jmedchem.6b00293","article-title":"New insights into human 17\u03b2-hydroxysteroid dehydrogenase type 14: First crystal structures in complex with a steroidal ligand and with a potent nonsteroidal inhibitor","volume":"59","author":"Bertoletti","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.steroids.2024.109529_b0735","doi-asserted-by":"crossref","first-page":"10719","DOI":"10.1021\/acs.jmedchem.6b01436","article-title":"First structure-activity relationship of 17\u03b2-hydroxysteroid dehydrogenase type 14 nonsteroidal inhibitors and crystal structures in complex with the enzyme","volume":"59","author":"Braun","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.steroids.2024.109529_b0740","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ejmech.2018.05.029","article-title":"Structure-based design and profiling of novel 17\u03b2-HSD14 inhibitors","volume":"155","author":"Braun","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.steroids.2024.109529_b0745","doi-asserted-by":"crossref","first-page":"e17027","DOI":"10.1200\/JCO.2024.42.16_suppl.e17027","article-title":"A phase I\/II study of enzalutamide in combination with indomethacin in men with castration-resistant prostate cancer (CRPC)","volume":"42","author":"Leibrandt","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.steroids.2024.109529_b0750","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/pros.24118","article-title":"Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative neoadjuvant trial in high-risk localized prostate cancer","volume":"81","author":"Graham","year":"2021","journal-title":"Prostate"}],"container-title":["Steroids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039128X24001673?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039128X24001673?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T00:57:27Z","timestamp":1733705847000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039128X24001673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":150,"alternative-id":["S0039128X24001673"],"URL":"https:\/\/doi.org\/10.1016\/j.steroids.2024.109529","relation":{},"ISSN":["0039-128X"],"issn-type":[{"value":"0039-128X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent advances in the development of 17beta-hydroxysteroid dehydrogenase inhibitors","name":"articletitle","label":"Article Title"},{"value":"Steroids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.steroids.2024.109529","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"109529"}}